The Technical Analyst
Dermata Therapeutics, [DRMA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Dermata Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
18.21% $0.338
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.25 mill |
| EPS: | -2.67 |
| P/E: | -0.130 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 6.66 mill |
| Avg Daily Volume: | 0.160 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.130 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.130 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.303 - 0.373 ( +/- 10.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-04 | Mento Steven J | Buy | 10 000 | Stock Option (Right to Buy) |
| 2024-01-04 | Proehl Gerald T | Buy | 125 000 | Stock Option (right to buy) |
| 2024-01-04 | Fisher Mary | Buy | 10 000 | Stock Option (Right to Buy) |
| 2024-01-04 | Scott Kathleen D. | Buy | 10 000 | Stock Option (Right to Buy) |
| 2024-01-04 | Sandler Andrew Seth | Buy | 10 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 98 transactions |
| Buy: 8 169 572 | Sell: 872 238 |
Forecast:
16:00 - $0.338
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.338
Forecast 2: 16:00 - $0.338
Forecast 3: 16:00 - $0.338
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.338 (18.21% ) |
| Volume | 0.276 mill |
| Avg. Vol. | 0.160 mill |
| % of Avg. Vol | 172.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DRMA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DRMA
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Latest Press Releases
2024-03-27 16:05:00 - Press Release
Dermata To Present At The Emerging Growth Conference On April 3, 2024
- dermata to provide a corporate update followed by a live question and answer session - san diego, ca / accesswire / march 27, 2024 / dermata therapeutics, inc. (nasdaq:drma; drmaw) ("dermata" or the "company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the emerging growth conference on april 3, 2024. this live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the company's ceo, gerry proehl in real time.
2024-03-21 16:05:00 - Press Release
Dermata Therapeutics Provides Corporate Update And Reports Full Year 2023 Financial Results
- initiated enrollment of dmt310 phase 3 spongilla treatment of acne research (star-1) clinical trial in q4 2023 - - raised $9.1 million in gross proceeds from three financings completed in 2023 - - received issuance of japanese patent for dmt410 for the treatment of hyperhidrosis - san diego, ca / accesswire / march 21, 2024 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the full year ended december 31, 2023. "it is an enormous accomplishment for our team to have successfully initiated the first of two dmt310 phase 3 clinical studies in acne," commented gerry proehl, dermata's chairman, president, and chief executive officer.
2024-02-01 09:00:00 - Press Release
Dermata To Present At The Emerging Growth Conference On February 7, 2024
- company to provide a corporate overview followed by a live question and answer session - san diego, ca / accesswire / february 1, 2024 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata" or the "company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the emerging growth conference on february 7, 2024. this live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the company's ceo, gerry proehl in real time.
2024-01-04 16:05:00 - Press Release
Dermata Expands Global Intellectual Patent Portfolio With Issuance Of Japanese Patent For Dmt410 For The Treatment Of Hyperhidrosis
- this is the company's first patent issued for dmt410, using its spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - the company is currently discussing partnership opportunities to advance development of dmt410 - - in 2022, the japanese prevalence of hyperhidrosis was 10%, with approximately 6% having primary axillary hyperhidrosis - san diego, ca / accesswire / january 4, 2024 / dermata therapeutics, inc. (nasdaq:drma, drmaw) ("dermata" or the "company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in japan for its dmt410 program for the treatment of hyperhidrosis...
2023-12-20 16:05:00 - Press Release
Dermata Enrolls First Patient In Pivotal Dmt310 Phase 3 Star-1 Clinical Trial For Acne
- about 550 patients will be treated once weekly for 12 weeks - - star-1 topline results expected in first quarter of 2025 - - acne affects about 50 million patients in the u.s. - san diego, ca / accesswire / december 20, 2023 / dermata therapeutics, inc. (nasdaq:drma, drmaw) ("dermata" or the "company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it successfully enrolled the first patient in its pivotal dmt310 phase 3 spongilla treatment for acne research (star-1) study. the star-1 study is the first of two phase 3 studies that, if positive, will be used by the company to support the filing of a new drug application (nda) for dmt310 for the treatment of moderate-to-severe acne.
Latest News
2024-03-27 16:05:00 - Accesswire
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on April 3, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl in real time.
2024-02-01 09:00:00 - Accesswire
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on February 7, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl in real time.
2024-01-05 08:31:59 - InvestorPlace
Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today?
Dermata Therapeutics (NASDAQ: DRMA ) stock is soaring higher on Friday after the clinical-stage medical dermatology company announced a new patent in Japan. This new patent covers DMT410 for the treatment of hyperhidrosis.
2023-11-17 10:31:36 - Zacks Investment Research
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
2023-06-13 16:15:00 - Accesswire
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced today that Dermata's CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET. The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.
2023-04-21 13:43:40 - Zacks Investment Research
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
2023-04-20 08:49:29 - InvestorPlace
Why Is Dermata Therapeutics (DRMA) Stock Up 22% Today?
Dermata Therapeutics (NASDAQ: DRMA ) stock is on the rise Thursday following an update concerning its moderate-to-severe acne treatment. The big news here is the FDA signed off on the company's ability to hold a Phase 3 clinical trial of DMT310.
2023-03-24 08:14:29 - InvestorPlace
Why Is Dermata Therapeutics (DRMA) Stock Up 23% Today?
Dermata Therapeutics (NASDAQ: DRMA ) stock is taking off on Friday despite a lack of news from the clinical-stage biotechnology company. While there are no press releases or filings that explain why DRMA stock is up today, traders are excited for some reason.
2023-01-03 06:00:00 - PennyStocks
Trading Penny Stocks in the New Year? 3 Tips
Which penny stocks are you buying this year? The post Trading Penny Stocks in the New Year?
2023-01-01 11:00:00 - PennyStocks
How to Increase Your Chances of Consistent Penny Stocks Profits
Use these tips to make money with penny stocks The post How to Increase Your Chances of Consistent Penny Stocks Profits appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.